News

University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway

April 2021, Cambridge, UK – o2h Ventures, a UK based fund manager through investment in its SEIS and EIS human health funds is excited to announce an investment into Stingray Bio Ltd, a new spin out from the University of Sussex supported by the Sussex Innovation Centre.


Stingray Bio is developing new novel small molecule inhibitors of the LMTK3 kinase signaling pathway to treat breast and other cancers. Stingray’s drug target rationale has been extensively validated by its founders, Professors Georgios Giamas and John Spencer of the University of Sussex.

Read more

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

 

Read more

April 2021 eNews

Click here to view the April 2021 edition of eNews.


Read more

PrecisionLife unveils new spin-out Synomics taking its proven analytics platform into animal and crop health sectors

PrecisionLife Ltd, leaders in combinatorial analytics, today unveils the launch of its new spin-out Synomics Ltd. Synomics will develop and market applications of the PrecisionLife® combinatorial analytics platform for the improvement of the health and yield of livestock and crops in sustainable agriculture and food production. Wheatsheaf Group, PrecisionLife’s lead investor has invested in Synomics, with PrecisionLife retaining a minority equity holding.

Read more

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

CAMBRIDGE, UK and NEW YORK, USA, 7 April March 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generation DDR targets to enhance Novartis’s Radioligand Therapies (RLT). 

Read more

Metrion Biosciences closes £2.7m new equity financing

Cambridge, UK, 06 April 2021: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced that it has secured £2.7m in new equity financing, including £2.25m from lead investor Gresham House Ventures. The funding will be used to expand Metrion’s laboratories in Cambridge, UK, invest in specialist equipment, develop its cell line library, and add GLP cardiac safety services. The financing will also enable the expansion of the Company’s business development activities.

Read more

A new era for UK-Japanese scientific relations

As the UK and Japan embark on a new trade deal, there are aspirations of greater collaboration and investment between the two nations. Dr. Jorg Taubel shares his thoughts on the future needs of the Japanese pharmaceutical market and how UK-Japanese scientific relations can support this in his recent article in Pharmaceutical Market Europe and PMLive.

Read more

Dive into Evotec’s New Science Pool!

Evotec is excited to be launching its new Science Pool- a content hub for scientific knowledge and resources including articles and whitepapers, videos and webinars, posters, guides, case studies and more!

The resources on the Science Pool feature exciting new research, insights into regulatory news and trends in the industry - enabling users to keep ahead of the game with respect to new developments in their respective fields. Opinions and reviews on current areas of science are shared on the Evotec blog with many of the articles focusing on new groundbreaking research.

Read more

ARECOR RECEIVES £2.8 MILLION GRANT AWARD FROM INNOVATE UK

Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin


Cambridge, UK., 31st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.

Read more

Cambridge Innovation Capital Becomes Latest Partner of One Nucleus

Cambridge, UK: 31 March 2021 - One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes facilitating connections between companies and with investors. Cambridge Innovation Capital (CIC), the renowned investor backing and building world-leading deeptech and life sciences companies in the Cambridge ecosystem, has become the latest company to join the One Nucleus Partner Programme.

Read more

Pages